CN111239406A - Hepatocyte growth factor latex immunoturbidimetry detection kit and preparation method and application thereof - Google Patents
Hepatocyte growth factor latex immunoturbidimetry detection kit and preparation method and application thereof Download PDFInfo
- Publication number
- CN111239406A CN111239406A CN202010054738.1A CN202010054738A CN111239406A CN 111239406 A CN111239406 A CN 111239406A CN 202010054738 A CN202010054738 A CN 202010054738A CN 111239406 A CN111239406 A CN 111239406A
- Authority
- CN
- China
- Prior art keywords
- protein
- acid
- tris
- growth factor
- hepatocyte growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a hepatocyte growth factor latex immunoturbidimetry detection kit, a preparation method and application thereof. The kit contains a reaction reagent R1, a reaction reagent R2, a calibrator and a quality control material; wherein the reaction reagent R1 contains: 50-150mmol/L of buffer, 200mmol/L of electrolyte, 0.5-2% w/w of coagulant, 0.05-0.5% w/w of stabilizer, 0.05-0.2% w/w of surfactant, 0.05-0.5% w/w of preservative and pH of 7.0-8.5; wherein, the reaction reagent R2 contains polystyrene microspheres coated by recombinant protein A protein G fusion protein combined with mouse anti-human hepatocyte growth factor antibody. The invention establishes a kit based on a quasi-homogeneous phase measurement technology and a preparation method thereof, and the kit can be used on a full-automatic biochemical analyzer and can obtain results only in 10 minutes. Compared with the existing method, the method is simple and convenient to operate, is rapid, and can meet the clinical requirements on simplicity and feasibility.
Description
Technical Field
The invention relates to a latex immunoturbidimetry detection kit, a preparation method and application thereof, in particular to a hepatocyte growth factor latex immunoturbidimetry detection kit, a preparation method and application thereof. The invention belongs to the technical field of medicines.
Background
Hepatocyte Growth Factor (HGF) is a polypeptide growth factor that has the effect of promoting the growth, migration and morphogenesis of various types of cells including hepatocytes, epithelial cells, endothelial cells, hematopoietic cells, and the like. It also participates in proliferation and migration of various cells, and has important induction effect on invasion and metastasis of various tumors.
A method for determining the concentration of hepatocyte growth factor in serum by enzyme-linked immunosorbent assay was reported as early as 1992 by M Takemura. Shiota G et al in 1995 reported a method of measuring the concentration of hepatocyte growth factor in serum by immunoradiometric method. 2005Uto H et al reported a method of rapid semi-quantitative Immunochromatography (IC) for determining hepatocyte growth factor concentration. Liu Youhua et al, 2002, applied for a method for measuring hepatocyte growth factor (application No. 02112853.7), which mainly applies enzyme-linked immunosorbent assay to measure hepatocyte growth factor. 2015, Zhang Ning of Tianjin medical university and the like, applied for the preparation of the single-chain antibody of the liver cancer marker and the application thereof (application number: 201510759337.5), and the kit is prepared by adopting enzyme linked immunosorbent assay technology in the patent. The principle of enzyme-linked immunoassay is as follows: coating the Hepatocyte Growth Factor (HGF) antibody in a 96-well microplate to prepare a solid phase carrier, respectively adding a standard substance or a specimen into the micropores, wherein the Hepatocyte Growth Factor (HGF) is combined with the antibody connected to the solid phase carrier, then adding a biotinylated Hepatocyte Growth Factor (HGF) antibody, washing the unbound biotinylated antibody, adding HRP-labeled avidin, thoroughly washing again, and adding a TMB substrate for color development. TMB is converted to blue by the catalysis of peroxidase and to the final yellow by the action of an acid. The shade of the color was positively correlated with Hepatocyte Growth Factor (HGF) in the sample. The absorbance (o.d. value) was measured at a wavelength of 450nm with a microplate reader, and the sample concentration was calculated. The kit components typically include: 1) an ELISA plate; 2) enzyme-labeled reagent; 3) a standard substance; 4) a calibrator diluent; 5) a sample diluent; 6) color developers (1 or 2); 7) a stop solution; 8) a wash liquor or a wash liquor concentrate. The operation steps comprise: adding an enzyme-labeled antibody, incubating, washing, adding a color developing agent, incubating, adding a stop solution, and measuring by an enzyme-labeled instrument. And calculating the measurement result. Enzyme-linked immunoassay is based on a non-homogeneous detection technique, which is a method of immobilizing antibodies on a solid support. The disadvantages are that: the kit has multiple components and multiple experimental steps, needs multiple steps of sample adding, incubation, cleaning, re-incubation, re-cleaning, color development and the like, is complex to operate, cannot realize automatic detection, and is easy to cause operation errors. In addition, the detection time is long, the method is suitable for detecting batch samples, is suitable for scientific research, and cannot meet the simple and easy requirements of clinical requirements.
Latex immunoturbidimetry has been increasingly applied to clinical testing projects due to its advantages of simple and convenient testing method, wide linear range, good stability, and the like, and can realize the detection of a large number of samples on a full-automatic biochemical analyzer. Latex immunoturbidimetry couples antibodies or antigens to the surface of nanospheres by physical adsorption or covalent bonding to form microsphere-antibody (antigen) complexes. The composite and the antigen (antibody) in the sample react through the antibody and the antigen to form microsphere-antibody-antigen aggregation particles, the aggregation particles are continuously increased along with the continuous occurrence of immune reaction, so that the light absorption value of the solution at a certain wavelength is obviously changed, and the concentration of the antigen (antibody) in the sample can be calculated by measuring the change of the light absorption value before and after the immune reaction, so that the aim of detecting and diagnosing diseases is fulfilled.
Disclosure of Invention
The invention aims to provide a hepatocyte growth factor latex immunoturbidimetry detection kit, and a preparation method and application thereof. The kit can be used on a full-automatic biochemical analyzer, can realize full-automatic detection, can obtain a result in 10 minutes, and has wide linear range and high sensitivity.
In order to achieve the purpose, the invention adopts the following technical means:
the invention relates to a hepatocyte growth factor latex immunoturbidimetry detection kit, which comprises a reaction reagent R1, a reaction reagent R2, a calibrator and a quality control material;
wherein the reaction reagent R1 contains: 50-150mmol/L of buffer, 200mmol/L of electrolyte, 0.5-2% w/w of coagulant, 0.05-0.5% w/w of stabilizer, 0.05-0.2% w/w of surfactant, 0.05-0.5% w/w of preservative and pH of 7.0-8.5;
wherein, the reaction reagent R2 contains polystyrene microspheres coated by recombinant protein A protein G fusion protein combined with mouse anti-human hepatocyte growth factor antibody.
Of these, preferred buffers are selected from Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid hemisodium salt), TES (N-Tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), PIPES (piperazine-N, N '-Bis (2-ethanesulfonic acid)), Bis-Tris Propane (Bis [ Tris (hydroxymethyl) aminopropane ]/1, 3-Bis [ Tris (hydroxymethyl) methylamino ] Propane), BES (N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), HEPES (N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid), At least one of TES (N-3- (hydroxymethyl) methyl-2-aminoethanesulfonic acid), DIPSO (3- [ N-bis (2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid), TAPSO (N-3- (hydroxymethyl) methylamino-2-hydroxypropanesulfonic acid), Tris (Tris-hydroxymethyl aminomethane), HEPPSO (4- (2-hydroxyethyl) piperazine-1-2-hydroxypropanesulfonic acid), POPSO (piperazine-1, 4-dihydroxypropanesulfonic acid), EPPS (4-hydroxyethylpiperazine propanesulfonic acid), TEA (triethanolamine), Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), phosphate;
wherein, preferably, the electrolyte is selected from at least one of sodium chloride, potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate and sodium bicarbonate;
wherein, preferably, the coagulant is selected from at least one of PEG6000, PEG8000 and polybrene;
wherein, the stabilizer is preferably selected from at least one of Bovine Serum Albumin (BSA), rabbit serum, bovine serum, mannitol and trehalose;
wherein, preferably, the surfactant is selected from at least one of Tween20, Tween 80, Triton 100 and polyoxyethylene lauryl ether;
among them, it is preferable that the preservative is at least one selected from the group consisting of sodium azide, 2-chloroacetamide, sodium dehydroacetate, sodium methyl paraben, sodium p-hydroxyglycinate, ethyl 4-hydroxybenzoate, 5-bromo-5-nitro-1, 3-dioxane (BND), 2-hydroxypyridine-N-oxide (Oxy-pyridine), imidazolidinyl urea, and Methylisothiazolinone (MIT).
Wherein, preferably, the recombinant protein A protein G fusion protein is a fusion protein of protein A and protein G obtained by a genetic engineering method, and comprises 5 Fc binding domains of Staphylococcus aureus protein A and 2 Fc binding domains of streptococcal protein G; the diameter of the polystyrene microsphere is 50nm-300nm, and the mass ratio of the recombinant protein A protein G fusion protein to the polystyrene microsphere is 100 mg-600 mg: 1g of the total weight of the composition.
Preferably, the polystyrene microsphere coated by the recombinant protein A protein G fusion protein is prepared by the following method: washing 1ml of 10% medium density carboxyl microspheres twice with 100mmol/L MES buffer solution with pH5.0, then suspending with 10ml of the above buffer solution, adding 20mg EDC, and slowly stirring for 15-20 min; centrifugally cleaning with 100mmol/L borax buffer solution of pH8.2 for 2 times, re-suspending the microspheres with 100mmol/L borax buffer solution of pH8.2, and stirring gently; adding 5ml of 20mmol/L pH7.4 phosphate buffer solution containing 5-7mg/ml recombinant protein A protein G fusion protein into the suspension, and slowly stirring at 18-30 deg.C for 2-4 hr; washing with borax buffer solution once, adding 10ml100mmol/L glycine buffer solution containing 1g/L BSA (bovine serum albumin) with pH8.2 for resuspension, slowly stirring and standing for 10 minutes; the suspension was washed twice with the buffer, resuspended in 10ml of 50mmol/L pH7.4 phosphate buffer containing 0.1G/L BSA and 1G/L NaN3 to make a suspension of recombinant protein A protein G fusion protein-coated polystyrene microspheres with a microsphere concentration of 10mg/ml, and stored at 2-8 ℃ until use.
Preferably, the polystyrene microsphere coated by the recombinant protein A protein G fusion protein combined with the mouse anti-human hepatocyte growth factor antibody is prepared by the following method:
washing the polystyrene microspheres coated with the recombinant protein A protein G fusion protein for 2 times by using an equal-volume antibody binding buffer solution (20mmol/L PBS, 0.5mol/L NaCl, pH 7.0), then discarding the supernatant, dissolving the mouse anti-human hepatocyte growth factor antibody in the antibody binding buffer solution with the same volume with the microspheres at the concentration of 80-200 mug/ml, adding the antibody solution into the washed microspheres, re-suspending the microspheres, and then, gently stirring for 30-60 minutes at the temperature of 10-30 ℃; centrifuging and removing supernatant, and washing the microspheres twice by using 1mol/LNaCl solution with the same volume; resuspending the microspheres in a stock solution;
wherein, preferably, the antibody binding buffer solution is 20mmol/LPBS containing 0.5mol/L NaCl and pH 7.0; the microsphere concentration in the storage solution is 10mg/ml, and the storage buffer solution contains: 100mM buffer, 0.01% w/w BSA, 0.05% w/w surfactant, 10mM EDTA, 0.1% w/w NaN3, pH 8.5.
Wherein, preferably, the buffer is selected from at least one of Tris, borax, carbonate, HEPPSO, POPSO, EPPS, TEA, Tricine, Bicine and TAPS; the surfactant is at least one selected from Tween20, Thestit, TritonX-100 and Brij 35.
Preferably, the calibrator is a series of standards respectively containing 0, 0.25, 0.5, 1.0, 2.0, 4.0ng/mL hepatocyte growth factor, and the series of standards further contains, in addition to hepatocyte growth factor: 50-150mmol/L of buffer, 100mM of sodium chloride, 5-10% w/w of excipient, 0.05-0.1% w/w of preservative and pH 7.0-8.0; after preparation, freeze drying is carried out;
wherein, preferably, the quality control product comprises: 50-150mmol/L of buffer, 100mM of sodium chloride, 5-10% w/w of excipient, 0.05-0.1% w/w of preservative, 0.4ng/mL or 1.5ng/mL of hepatocyte growth factor and pH7.0-8.0, and freeze-drying after preparation;
of these, preferred buffers are selected from Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid hemisodium salt), TES (N-Tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), PIPES (piperazine-N, N '-Bis (2-ethanesulfonic acid)), Bis-Tris Propane (Bis [ Tris (hydroxymethyl) aminopropane ]/1, 3-Bis [ Tris (hydroxymethyl) methylamino ] Propane), BES (N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), HEPES (N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid), At least one of TES (N-3- (hydroxymethyl) methyl-2-aminoethanesulfonic acid), DIPSO (3- [ N-bis (2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid), TAPSO (N-3- (hydroxymethyl) methylamino-2-hydroxypropanesulfonic acid), Tris (Tris-hydroxymethyl aminomethane), HEPPSO (4- (2-hydroxyethyl) piperazine-1-2-hydroxypropanesulfonic acid), POPSO (piperazine-1, 4-dihydroxypropanesulfonic acid), EPPS (4-hydroxyethylpiperazine propanesulfonic acid), TEA (triethanolamine), Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), phosphate;
wherein, preferably, the excipient is selected from at least one of BSA, mannitol, trehalose and lactose;
among them, it is preferable that the preservative is at least one selected from the group consisting of sodium azide, 2-hydroxypyridine-N-oxide (Oxy-pyridine), imidazolidinyl urea, and Methylisothiazolinone (MIT).
Preferably, the calibrator and the quality control product are subpackaged into penicillin bottles according to 0.5 ml/bottle, and the subpackaged calibrator or quality control product is pre-frozen at the temperature of-20 ℃ for more than 5 hours; setting a freeze-drying program according to the temperature of a clapboard between-40 ℃ for 3 hours and-20 ℃ for 5 hours to 0 ℃ for 8 hours to 5 ℃ for 4 hours to 10 ℃ for 4 hours to 20 ℃ for 2 hours, starting a freeze dryer, putting a sample when the temperature of the clapboard of the freeze dryer is reduced to-50 ℃, and starting the freeze-drying program.
Furthermore, the invention also provides application of the latex immunoturbidimetry detection kit in preparation of a reagent for detecting human hepatocyte growth factor.
The detection principle of the kit is as follows: when a sample to be tested is mixed with a reagent, HGF in the sample reacts specifically with an anti-HGF antibody to form an insoluble complex, causing an increase in turbidity. The turbidity was measured with an absorbance of 570-700 nm. Calibration curves for HGF concentration and absorbance can be obtained by measuring a series of calibrators. And comparing the absorbance generated by the reaction of the sample and the antibody with a calibration curve to determine the concentration of HGF in the sample.
The operation steps are as follows: the reagent box is put into a reagent bin of the full-automatic biochemical instrument, the calibrator, the quality control material and the sample are put into a sample bin of the full-automatic biochemical instrument, analysis parameters are set on the full-automatic biochemical instrument, the instrument is started, and the instrument automatically measures and calculates results.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention establishes a kit based on a quasi-homogeneous phase measurement technology and a preparation method thereof, and the kit can be used on a full-automatic biochemical analyzer and can obtain results only in 10 minutes. The prior art is manual operation, and results can be obtained in 30-45 minutes. Compared with the existing method, the method is simple, convenient and quick to operate;
2. the recombinant protein A protein G fusion protein containing 5 Fc binding domains of staphylococcus aureus protein A and 2 Fc binding domains of streptococcal protein G is obtained by a genetic engineering method, the binding capacity is greatly improved compared with that of a single fusion protein of protein A and protein G, and the fusion protein has stronger Fc segment binding capacity. Binds to IgG Fc fragment of most mammals (including: human, goat, sheep, rabbit, guinea pig, horse, pig, monkey, mouse, etc.). Currently, recombinant protein A protein G fusion protein agarose purification resin is commonly used for antibody purification. The invention coats the recombinant protein A protein G fusion protein to the surface of polystyrene carboxyl microsphere of 50nm-300nm to prepare protein A/G microsphere, and the microsphere is used for preparing latex antibody in HGF latex immunoturbidimetry diagnostic reagent, which can obviously improve the efficiency of immunoreaction.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 preparation of kits and evaluation of analytical Properties
1. Preparation of the kit
(1) Preparation of reagent R1
Materials: tris (analytical grade), sodium chloride (analytical grade), Bovine Serum Albumin (BSA) (high purity), PEG6000 (purity > 98%), tween20 (reagent grade), sodium azide (purity > 99%).
Purified water of an in vitro diagnostic reagent (about 400 ml) was added to a 500ml beaker, and 6.05g of Tris was added thereto and dissolved substantially completely under stirring. The pH was adjusted to 7.4-7.5 with HCl. 4.5g of sodium chloride, 0.5g of PEG60000.5 g of BSA, 1g of sodium azide and 200.5 g of Tween were added and stirred to be completely dissolved, and the pH was precisely adjusted to 7.40. + -. 0.10. The volume of the solution is up to 510g by using in vitro diagnostic reagent purified water. Filtration through a 0.22 μm aqueous filter.
(2) Preparation of reagent R2
A. Preparation of polystyrene microspheres coated with recombinant protein A protein G fusion protein (recombinant protein A/G)
Materials: recombinant protein a/G (containing 5 Fc binding domains of staphylococcus aureus protein a and 2 Fc binding domains of streptococcal protein G, > 95% purity, purchased from shanghai proshen biotechnology limited), medium density carboxyl microspheres (10%, 150 nm); MES buffer (pH 5.0,100 mmol/L); borax buffer (pH8.2,100 mmol/L); EDAC (purity > 98%); glycine buffer (pH8.2,100mmol/L)
The preparation process comprises the following steps:
after washing 1ml of 10% medium density carboxyl microspheres twice with MES buffer (100mmol/L) pH5.0, 10ml of the above buffer was used to resuspend and 20mg EDC was added, and the mixture was stirred slowly for 15-20 minutes. After 2 centrifugation washes with pH8.2 borax buffer (100mmol/L), the microspheres were resuspended in 5ml of this buffer and gently stirred. 5ml of a phosphate buffer containing recombinant protein A/G (recombinant protein A/G5-7 mg/ml, phosphate 20mmol/L, pH7.4) was added to the suspension. Slowly stirring for 2-4 hours at 18-30 ℃. After washing once with borax buffer, 10ml of 100mmol/L glycine buffer (pH8.2) containing 1g/L BSA was added for resuspension, and the mixture was allowed to stand with slow stirring for 10 minutes. The protein A/G microspheres were washed twice with this buffer and resuspended in 10ml of phosphate buffer (PBS 50mmol/L, BSA 0.1G/L, NaN 31G/L, pH7.4) to give a protein A/G microsphere suspension with a microsphere concentration of 10 mg/ml. Storing at 2-8 deg.C for use.
Preparation of polystyrene microsphere coated by recombinant protein A protein G fusion protein combined with mouse anti-human hepatocyte growth factor antibody
Materials: and (B) preparing the protein A/G microspheres in the step A. Mouse monoclonal antibody against human hepatocyte growth factor. Antibody binding buffer (20mM PBS, 0.5M NaCl, pH 7.0). Washing solution (1M NaCl) was combined. Storage buffer (100mM Tris pH8.2, 0.01% w/w BSA, 0.05% w/w Tween20, 10mM EDTA, 0.1% w/w NaN3, bovine serum 10 ml/L.)
The method comprises the following steps:
20ml of the protein A/G beads (10mg/ml) prepared in step A were washed 2 times with 20ml of an antibody-binding buffer (20mM PBS, 0.5M NaCl, pH 7.0) and the supernatant was discarded. The antibody to be bound to hepatocyte growth factor was dissolved in 20ml of antibody binding buffer to protein A/G microspheres at a concentration of approximately 100. mu.g/ml. The antibody solution was added to the washed protein A/G microspheres, the microspheres were resuspended, and then gently stirred at room temperature (10-30 ℃) for 40 minutes. The supernatant was discarded by centrifugation, and the microspheres were washed twice with 20ml of 1M NaCl solution. After 30ml of storage buffer solution is resuspended, the mixture is fully stirred and filtered by a 0.45 mu m water system filter membrane, and the polystyrene microsphere coated by the recombinant protein A protein G fusion protein combined with the mouse anti-human hepatocyte growth factor antibody is obtained.
(3) Preparation of hepatocyte growth factor calibrator and quality control product
A. Preparing a buffer solution: 400ml of in-vitro diagnostic reagent purified water is added into a 500ml beaker, then Tris3.025g, sodium chloride 4.38g, BSA 0.5g, mannitol 25g and sodium azide 1g are added, after complete dissolution, the pH is adjusted to 7.4 +/-0.1, and finally the volume is constant to 500ml, so that the final concentration of each substance is 50mmol/L Tris, 150mmol/L sodium chloride, 1g/L BSA, 50g/L mannitol and 2g/L sodium azide. The prepared solution was filtered through a 0.22 μm aqueous filter.
B. Preparation of calibrator and quality control material
80mL of buffer solution is added into a 100mL beaker, hepatocyte growth factor is added, and finally the volume is determined to be 100mL, so that the final concentration is 4 ng/mL. After stirring for 30-40 minutes, the mixture was filtered through a 0.22 μm aqueous filter.
The 4ng/mL high value calibrator was diluted with buffer to a final concentration of 0.25, 0.5, 1, 2, 4, 0.4, 1.5ng/mL, using the specific dilution method shown in Table 1:
TABLE 1
C. Freeze drying of calibrator and quality control material
The calibrator and the quality control material are respectively dispensed into penicillin bottles according to the volume of 0.5 ml. Pre-freezing the packaged calibrator or quality control product at-20 deg.C for more than 5 hr. The lyophilization procedure was set according to the temperature of the septum-40 ℃ for 3 hours-20 ℃ for 5 hours-0 ℃ for 8 hours-5 ℃ for 4 hours-10 ℃ for 4 hours-20 ℃ for 2 hours. Starting the freeze dryer, putting the sample when the temperature of a clapboard of the freeze dryer is reduced to-50 ℃, and starting a freeze drying program.
2. Evaluation of assay Performance of the kit
A. Detection conditions and detection parameters
AU640 full-automatic biochemical instrument for detecting instrument
Detecting parameters: dominant wavelength: 600nm
R1 reagent: 150ul
R2 reagent: 50ul
S sample: 20ul of
The reaction direction is as follows: liter reaction
The method comprises the following steps: END
Read points A1150-180S A2400-500S
B. Detecting linearity
High-value samples with 4ng/mL human serum are diluted and mixed into samples (xi) with 8 different gradients of dilution ratios of 0, 1/32, 1/16, 1/8, 1/4, 1/2, 3/4 and 1, and the reagents (kit) are respectively tested. Samples at each dilution were tested 3 times, and the mean value (yi) of the measurement results was determined. The linear regression equation y is 0.1411+3.8724x with the dilution concentration (xi) as an independent variable and the measurement result mean (yi) as a dependent variable. The correlation coefficient (r) of the linear regression was calculated as 0.9991.
C. Sensitivity (lowest detection limit)
The kit prepared by the invention is used for 20 times by taking a 4% human serum albumin solution as a blank sample, and the result shows that the average value of the absorbance change is 1.0981 and the standard deviation SD is 0.0312. The mean of the absorbance changes of the blank plus two times the standard deviation is 1.1606. The low-value standard solution is diluted by a blank sample to prepare three samples with the concentrations of 0.0625, 0.125 and 0.25ng/mL, the three samples are measured by the kit prepared by the invention for 20 times, and the average value of the absorbance change is 1.1009(1.0567-1.1522), 1.1733(1.1231-1.2376) and 1.2545(1.1901-1.3059), which shows that the sensitivity of the kit can reach 0.25 ng/mL.
D. Repeatability of
The 2 quality controls prepared by the present invention were continuously measured 20 times each, and the mean, standard deviation, and Coefficient of Variation (CV) were calculated. The quality control result with the determination concentration of 0.4ng/mL is the measurement mean value 0.3985, the standard deviation of 0.0300 and the coefficient of variation of 7.52 percent. The quality control of the determination concentration is 1.5ng/mL, the measurement mean value is 1.4980, the standard deviation is 0.0613, and the coefficient of variation is 4.09%.
E. Human serum reference range
120 normal human serum samples were tested, with a mean value of 0.24 and a standard deviation of 0.54. The mean plus-minus-two times SD is taken as the reference range of the healthy person, and the reference range of the healthy person is determined to be less than 0.34ng/mL in consideration of the sensitivity of the method of 0.25 ng/mL.
Claims (9)
1. A kit for detecting hepatocyte growth factor latex immunoturbidimetry is characterized in that the kit contains a reaction reagent R1, a reaction reagent R2, a calibrator and a quality control material;
wherein the reaction reagent R1 contains: 50-150mmol/L of buffer, 100-200mmol/L of electrolyte, 0.5-2% w/w of coagulant, 0.05-0.5% w/w of stabilizer, 0.05-0.2% w/w of surfactant, 0.05-0.5% w/w of preservative, and pH 7.0-8.5;
wherein, the reaction reagent R2 contains polystyrene microspheres coated by recombinant protein A protein G fusion protein combined with mouse anti-human hepatocyte growth factor antibody.
2. The hepatocyte growth factor latex immunoturbidimetry assay kit of claim 1, wherein the buffer is selected from Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid hemisodium salt), TES (N-Tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), PIPES (piperazine-N, N' -Bis (2-ethanesulfonic acid)), Bis-Tris Propane (Bis [ Tris (hydroxymethyl) aminopropane ]/1, 3-Bis [ Tris (hydroxymethyl) methylamino ] Propane), BES (N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), HEPES (N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid), TES (N-3- (hydroxymethyl) methyl-2-aminoethanesulfonic acid), DIPSO (3- [ N-N-bis (2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid), TAPSO (N-3- (hydroxymethyl) methylamino-2-hydroxypropanesulfonic acid), Tris (Tris), HEPSO (4- (2-hydroxyethyl) piperazine-1-2-hydroxypropanesulfonic acid), at least one of POPSO (piperazine-1, 4-dihydroxypropanesulfonic acid), EPPS (4-hydroxyethylpiperazine propanesulfonic acid), TEA (triethanolamine), Tricine (N-tris- (hydroxymethyl) methylaminoacetic acid) and phosphate;
the electrolyte is selected from at least one of sodium chloride, potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate and sodium bicarbonate;
the coagulant is at least one selected from PEG6000, PEG8000 and polybrene;
the stabilizer is selected from at least one of Bovine Serum Albumin (BSA), rabbit serum, bovine serum, mannitol and trehalose;
the surfactant is selected from at least one of Tween20, Tween 80, Triton 100 and polyoxyethylene lauryl ether;
the preservative is selected from at least one of sodium azide, 2-chloroacetamide, sodium dehydroacetate, sodium methyl paraben, sodium p-hydroxy glycinate, ethyl 4-hydroxybenzoate, 5-bromo-5-nitro-1, 3-dioxane (BND), 2-hydroxypyridine-N-oxide (Oxy-PYRION), imidazolidinyl urea and Methylisothiazolinone (MIT).
3. The kit according to claim 1, wherein the recombinant protein A protein G fusion protein is a fusion protein of protein A and protein G obtained by genetic engineering, and comprises 5 Fc binding domains of Staphylococcus aureus protein A and 2 Fc binding domains of streptococcal protein G; the diameter of the polystyrene microsphere is 50nm-300nm, and the mass ratio of the recombinant protein A protein G fusion protein to the polystyrene microsphere is 100 mg-600 mg: 1g of the total weight of the composition.
4. The kit for detecting the hepatocyte growth factor latex immunoturbidimetry according to claim 1, wherein the polystyrene microspheres coated with the recombinant protein A protein G fusion protein are prepared by the following method: washing 1ml of 10% medium density carboxyl microspheres twice with 100mmol/L MES buffer solution with pH5.0, then suspending with 10ml of the above buffer solution, adding 20mg EDC, and slowly stirring for 15-20 min; centrifugally cleaning with 100mmol/L borax buffer solution of pH8.2 for 2 times, re-suspending the microspheres with 100mmol/L borax buffer solution of pH8.2, and stirring gently; adding 5ml of 20mmol/L pH7.4 phosphate buffer solution containing 5-7mg/ml recombinant protein A protein G fusion protein into the suspension, and slowly stirring at 18-30 deg.C for 2-4 hr; washing with borax buffer solution once, adding 10ml100mmol/L glycine buffer solution containing 1g/L BSA (bovine serum albumin) with pH8.2 for resuspension, slowly stirring and standing for 10 minutes; the suspension was washed twice with the buffer, resuspended in 10ml of 50mmol/L pH7.4 phosphate buffer containing 0.1G/L BSA and 1G/L NaN3 to make a suspension of recombinant protein A protein G fusion protein-coated polystyrene microspheres with a microsphere concentration of 10mg/ml, and stored at 2-8 ℃ until use.
5. The kit for detecting the hepatocyte growth factor latex immunoturbidimetry according to claim 1, wherein the polystyrene microsphere coated with the recombinant protein A protein G fusion protein combined with the mouse anti-human hepatocyte growth factor antibody is prepared by the following method:
washing the polystyrene microspheres coated with the recombinant protein A protein G fusion protein for 2 times by using an equal-volume antibody binding buffer solution (20mmol/L PBS, 0.5mol/L NaCl, pH 7.0), then discarding the supernatant, dissolving the mouse anti-human hepatocyte growth factor antibody in the antibody binding buffer solution with the same volume with the microspheres at the concentration of 80-200 mug/ml, adding the antibody solution into the washed microspheres, re-suspending the microspheres, and then, gently stirring for 30-60 minutes at the temperature of 10-30 ℃; centrifuging and discarding the supernatant, and washing the microspheres twice by using 1mol/L NaCl solution with the same volume; resuspending the microspheres in a stock solution; preferably, the antibody binding buffer solution contains 0.5mol/L NaCl, pH7.0 20mmol/L PBS; the microsphere concentration in the storage solution is 10mg/ml, and the storage buffer solution contains: 100mM buffer, 0.01% w/w BSA, 0.05% w/w surfactant, 10mM EDTA, 0.1% w/w NaN3, pH 8.5.
6. The hepatocyte growth factor latex immunoturbidimetry assay kit of claim 5, wherein the buffer is selected from at least one of Tris, borax, carbonate, HEPPSO, POPSO, EPPS, TEA, Tricine, Bicine, TAPS; the surfactant is at least one selected from Tween20, Thestit, TritonX-100 and Brij 35.
7. The kit according to claim 1, wherein the calibrator is a series of standards respectively containing 0, 0.25, 0.5, 1.0, 2.0, 4.0ng/mL hepatocyte growth factor, and the series of standards further contains, in addition to hepatocyte growth factor: 50-150mmol/L of buffer, 100mM of sodium chloride, 5-10% w/w of excipient, 0.05-0.1% w/w of preservative and pH 7.0-8.0; after preparation, freeze drying is carried out;
the quality control product comprises: 50-150mmol/L of buffer, 100mM of sodium chloride, 5-10% w/w of excipient, 0.05-0.1% w/w of preservative, 0.4ng/mL or 1.5ng/mL of hepatocyte growth factor and pH7.0-8.0, and freeze-drying after preparation;
of these, preferred buffers are selected from Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid hemisodium salt), TES (N-Tris (hydroxymethyl) methyl-2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), PIPES (piperazine-N, N '-Bis (2-ethanesulfonic acid)), Bis-Tris Propane (Bis [ Tris (hydroxymethyl) aminopropane ]/1, 3-Bis [ Tris (hydroxymethyl) methylamino ] Propane), BES (N-Bis (2-hydroxyethyl) -2-aminoethanesulfonic acid), MOPS (3- (N-morpholino) ethanesulfonic acid), HEPES (N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid), At least one of TES (N-3- (hydroxymethyl) methyl-2-aminoethanesulfonic acid), DIPSO (3- [ N-bis (2-hydroxyethyl) amino ] -2-hydroxypropanesulfonic acid), TAPSO (N-3- (hydroxymethyl) methylamino-2-hydroxypropanesulfonic acid), Tris (Tris-hydroxymethyl aminomethane), HEPPSO (4- (2-hydroxyethyl) piperazine-1-2-hydroxypropanesulfonic acid), POPSO (piperazine-1, 4-dihydroxypropanesulfonic acid), EPPS (4-hydroxyethylpiperazine propanesulfonic acid), TEA (triethanolamine), Tricine (N-Tris- (hydroxymethyl) methylaminoacetic acid), phosphate;
wherein, preferably, the excipient is selected from at least one of BSA, mannitol, trehalose and lactose;
among them, it is preferable that the preservative is at least one selected from the group consisting of sodium azide, 2-hydroxypyridine-N-oxide (Oxy-pyridine), imidazolidinyl urea, and Methylisothiazolinone (MIT).
8. The kit for detecting the hepatocyte growth factor latex immunoturbidimetry according to claim 7, wherein the calibrator and the quality control materials are subpackaged into penicillin bottles according to 0.5ml per bottle, and the subpackaged calibrator or quality control materials are pre-frozen at-20 ℃ for more than 5 hours; setting a freeze-drying program according to the temperature of a clapboard between-40 ℃ for 3 hours and-20 ℃ for 5 hours to 0 ℃ for 8 hours to 5 ℃ for 4 hours to 10 ℃ for 4 hours to 20 ℃ for 2 hours, starting a freeze dryer, putting a sample when the temperature of the clapboard of the freeze dryer is reduced to-50 ℃, and starting the freeze-drying program.
9. Use of the latex immunoturbidimetric assay kit of any of claims 1-8 in the preparation of a reagent for detecting hepatocyte growth factor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010054738.1A CN111239406B (en) | 2020-01-17 | 2020-01-17 | Hepatocyte growth factor latex immunonephelometry detection kit and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010054738.1A CN111239406B (en) | 2020-01-17 | 2020-01-17 | Hepatocyte growth factor latex immunonephelometry detection kit and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111239406A true CN111239406A (en) | 2020-06-05 |
| CN111239406B CN111239406B (en) | 2023-06-30 |
Family
ID=70872762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010054738.1A Active CN111239406B (en) | 2020-01-17 | 2020-01-17 | Hepatocyte growth factor latex immunonephelometry detection kit and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111239406B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112326956A (en) * | 2020-12-03 | 2021-02-05 | 安徽大千生物工程有限公司 | Tumor specific growth factor latex enhanced immunoturbidimetry detection kit and preparation method thereof |
| CN113189341A (en) * | 2021-02-26 | 2021-07-30 | 苏州优诺康生物技术有限公司 | Human heparin binding protein immunoturbidimetry detection reagent and application thereof |
| CN113834942A (en) * | 2021-11-02 | 2021-12-24 | 河北特温特生物科技发展有限公司 | Placenta growth factor quality control product and preparation method thereof |
| CN113985029A (en) * | 2021-10-25 | 2022-01-28 | 中元汇吉生物技术股份有限公司 | Composition suitable for improving stability of immunoturbidimetric reagent |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695405A (en) * | 2002-09-30 | 2005-11-09 | 贝克顿·迪金森公司 | Cell adhesion resisting surfaces |
| US20110301057A1 (en) * | 2010-06-03 | 2011-12-08 | New York University | In situ oriented immobilization of proteins on a support |
| CN103097417A (en) * | 2010-04-20 | 2013-05-08 | 根马布股份公司 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
| CN103184229A (en) * | 2011-12-30 | 2013-07-03 | 本元正阳基因技术有限公司 | Recombinant protein A/G gene and preparation and application of expression product of recombinant protein A/G gene |
| EP2693214A1 (en) * | 2011-03-31 | 2014-02-05 | Sekisui Medical Co., Ltd. | Latex particle for measurement reagent, sensitized latex particle, and measurement reagent for immunonephelometry |
| US20140377881A1 (en) * | 2011-12-28 | 2014-12-25 | Sekisui Medical Co., Ltd. | Latex particles for measuring particle agglutination |
| CN107589266A (en) * | 2017-08-09 | 2018-01-16 | 上海原科实业发展有限公司 | A kind of VEGF latex enhancing immune is than turbid kit and its application |
| CN108318698A (en) * | 2017-01-17 | 2018-07-24 | 天津市协和医药科技集团有限公司 | A kind of fecal occult blood latex enhancing Immunoturbidimetric kit |
| CN109738626A (en) * | 2019-02-19 | 2019-05-10 | 上海复星长征医学科学有限公司 | NGAL latex immunoturbidimetry detection kit and preparation method thereof |
-
2020
- 2020-01-17 CN CN202010054738.1A patent/CN111239406B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695405A (en) * | 2002-09-30 | 2005-11-09 | 贝克顿·迪金森公司 | Cell adhesion resisting surfaces |
| CN103097417A (en) * | 2010-04-20 | 2013-05-08 | 根马布股份公司 | Heterodimeric antibody FC-containing proteins and methods for production thereof |
| US20110301057A1 (en) * | 2010-06-03 | 2011-12-08 | New York University | In situ oriented immobilization of proteins on a support |
| EP2693214A1 (en) * | 2011-03-31 | 2014-02-05 | Sekisui Medical Co., Ltd. | Latex particle for measurement reagent, sensitized latex particle, and measurement reagent for immunonephelometry |
| US20140377881A1 (en) * | 2011-12-28 | 2014-12-25 | Sekisui Medical Co., Ltd. | Latex particles for measuring particle agglutination |
| CN103184229A (en) * | 2011-12-30 | 2013-07-03 | 本元正阳基因技术有限公司 | Recombinant protein A/G gene and preparation and application of expression product of recombinant protein A/G gene |
| CN108318698A (en) * | 2017-01-17 | 2018-07-24 | 天津市协和医药科技集团有限公司 | A kind of fecal occult blood latex enhancing Immunoturbidimetric kit |
| CN107589266A (en) * | 2017-08-09 | 2018-01-16 | 上海原科实业发展有限公司 | A kind of VEGF latex enhancing immune is than turbid kit and its application |
| CN109738626A (en) * | 2019-02-19 | 2019-05-10 | 上海复星长征医学科学有限公司 | NGAL latex immunoturbidimetry detection kit and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| DOUDOU LOU等: "Fluorescent Nanoprobes with Oriented Modified Antibodies to Improve Lateral Flow Immunoassay of Cardiac Troponin I", ANAL. CHEM., vol. 90, pages 6502 - 6508 * |
| 刘琳琳: "免疫微球检测金黄色葡萄球菌与链球菌研究", 中国热带医学, vol. 8, no. 2, pages 193 - 195 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112326956A (en) * | 2020-12-03 | 2021-02-05 | 安徽大千生物工程有限公司 | Tumor specific growth factor latex enhanced immunoturbidimetry detection kit and preparation method thereof |
| CN113189341A (en) * | 2021-02-26 | 2021-07-30 | 苏州优诺康生物技术有限公司 | Human heparin binding protein immunoturbidimetry detection reagent and application thereof |
| CN113985029A (en) * | 2021-10-25 | 2022-01-28 | 中元汇吉生物技术股份有限公司 | Composition suitable for improving stability of immunoturbidimetric reagent |
| CN113834942A (en) * | 2021-11-02 | 2021-12-24 | 河北特温特生物科技发展有限公司 | Placenta growth factor quality control product and preparation method thereof |
| CN113834942B (en) * | 2021-11-02 | 2024-02-02 | 河北特温特生物科技发展有限公司 | Placenta growth factor quality control product and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111239406B (en) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111239406B (en) | Hepatocyte growth factor latex immunonephelometry detection kit and application thereof | |
| CN111679086B (en) | HBP magnetic particle chemiluminescence detection kit and preparation method thereof | |
| CN108414748B (en) | Detection test strip and detection method for THSD7A antibody | |
| JP4668768B2 (en) | Immunoassay method and non-specific reaction suppression method | |
| CN110687286A (en) | Latex enhanced immunoturbidimetry kit | |
| EP2295969B1 (en) | Method for enhancing sensitivity or method for avoiding influence of hemoglobin in immunological measurement | |
| CN112782156B (en) | Chitinase 3-like protein 1 kit and preparation method thereof | |
| CN110007074B (en) | Kit for detecting C-reactive protein, preparation method and application thereof | |
| CN110806487A (en) | Kit for detecting human heparin binding protein and preparation method thereof | |
| EP1801590B1 (en) | Method of assaying antigen and reagent therefor | |
| JP3623657B2 (en) | Nonspecific reaction inhibitor, immunoassay reagent and immunoassay method | |
| US4971904A (en) | Heterogeneous immunoassay | |
| WO2022152147A1 (en) | Latex enhanced competitive turbidimetric immunoassay detection method and kit | |
| CN113866406B (en) | Kit for specifically detecting sugar-deficient transferrin | |
| JP3899029B2 (en) | Immunological analysis method | |
| US20220018856A1 (en) | Antibody conjugate | |
| KR20010025027A (en) | Immunoassay reagents and immunoassay method | |
| US20030143758A1 (en) | Insoluble carrier particle nephelometric immunoassay reagent | |
| CN114805586A (en) | anti-MxA monoclonal antibody composition and application thereof | |
| CN113219181A (en) | Kit for quantitatively detecting serum amyloid A and preparation method thereof | |
| CN111983213A (en) | Protein A/G microsphere, latex antibody and kit | |
| CN114200129B (en) | Hematuria simultaneous detection kit of tissue metalloproteinase inhibitor-2 latex immunoturbidimetry | |
| JP4616516B2 (en) | Immunological assay | |
| CN115598344A (en) | Detection kit for fecal pancreatic elastase 1 and preparation method thereof | |
| CN114062678A (en) | MMP-7 detection kit, preparation method and detection method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |